319 related articles for article (PubMed ID: 30607457)
1. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
[TBL] [Abstract][Full Text] [Related]
2. Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse R; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
J Bone Miner Res; 2019 Nov; 34(11):2001-2011. PubMed ID: 31402509
[TBL] [Abstract][Full Text] [Related]
3. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
4. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Thomasius F; Palacios S; Alam A; Boolell M; Vekeman F; Gauthier G
Osteoporos Int; 2022 Jan; 33(1):217-228. PubMed ID: 34490504
[TBL] [Abstract][Full Text] [Related]
5. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis medication and reduced mortality risk in elderly women and men.
Center JR; Bliuc D; Nguyen ND; Nguyen TV; Eisman JA
J Clin Endocrinol Metab; 2011 Apr; 96(4):1006-14. PubMed ID: 21289270
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
11. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
Bondo L; Eiken P; Abrahamsen B
Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
[TBL] [Abstract][Full Text] [Related]
13. Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Hayes KN; Ban JK; Athanasiadis G; Burden AM; Cadarette SM
Osteoporos Int; 2019 Nov; 30(11):2311-2319. PubMed ID: 31317249
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
[TBL] [Abstract][Full Text] [Related]
16. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and mortality: confounding in observational studies?
Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
[TBL] [Abstract][Full Text] [Related]
18. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
19. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
20. Risk of atypical femoral fracture during and after bisphosphonate use.
Schilcher J; Koeppen V; Aspenberg P; Michaëlsson K
Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
